Dr. Wamhoff is a founder of HemoShear where he co-developed HemoShear’s REVEAL-Tx™ drug discovery platform.
Susan Klees, HemoShear vice president of communications, has been appointed by Governor Ralph Northam to the Virginia Rare Disease Council.
HemoShear Therapeutics, Inc. has announced that the first two patients have been dosed in Phase 2 clinical trial of HST5040.
HemoShear Therapeutics, Inc. has raised $40 million in funding that will enable the company to complete a phase 2 study of its lead compound.
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
This award will enable HemoShear to have more frequent interactions with the FDA, as well as eligibility for accelerated approval, priority review, and rolling submission of a new drug application.